Generation Bio Co.

GBIO

Explore Our Financial Data > Companies > Generation Bio Co.
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
GBIO
CIK0001733294
SIC2834
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupPharmaceutical Preparations

Contact

Address301 BINNEY STREET, CAMBRIDGE, MA, 02142
Website generationbio.com
Phone857-529-5908
CEOCameron G. McDonough
Employees150

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$24.56 million
Pre-Tax Income$-82.65 million
Net Income$-71.93 million
Net Income to Common$-71.93 million
EPS$-1.08
View All
Balance Sheet
Cash$50.89 million
Assets$201.35 million
Liabilities$128.02 million
Common Equity$73.33 million
Liabilities & Equity$201.35 million
View All
Cash Flow Statement
Net Income$-71.93 million
Cash From Operating Activities$-85.23 million
Cash From Investing Activities$98.04 million
Cash From Financing Activities$368,000.00
Change in Cash$13.18 million
View All
Calculations
NOPAT$-56.95 million
EBITDA$-83.12 million
Price to EarningsN/A
Price to Book$0.52
ROE-70.06%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Generation Bio Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, today announced that, on July 1, 2025, the company granted equity awards to one new employee, pursuant to the company’s 2025 Inducement Stock Incentive Plan, as an inducement material to such new employee’s entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4)

Article Link

We're Keeping An Eye On Generation Bio's (NASDAQ:GBIO) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Article Link

Generation Bio to Present at the 2025 Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will present at the Jefferies Global Healthcare Conference on Wednesday, June 4th at 8:10 a.m. ET. A live webcast of the presentation will be available on the investor section of the company’s website at investors.generati

Article Link

Generation Bio Co. (GBIO) Reports Q1 Loss, Tops Revenue Estimates

Generation Bio (GBIO) delivered earnings and revenue surprises of 12% and 464.23%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Article Link

Generation Bio Reports Recent Business Highlights and First Quarter 2025 Financial Results

- Company continues to advance its strategy to develop first-in-class treatments for T cell-driven autoimmune diseases using its cell-targeted lipid nanoparticle (ctLNP) technology to deliver siRNA - Lead target and portfolio strategy to be announced mid-2025 - Cash balance of $157.6 million expected to fund operations into 2H 2027 CAMBRIDGE, MASS., May 07, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company working to change what’s possible for people living with

Article Link